Selected article for: "abrupt discontinuation and acute respiratory"
Author: Palandri, Francesca; Breccia, Massimo; De Stefano, Valerio; Passamonti, Francesco
Title: Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
  • Cord-id: r42bccr9
  • Document date: 2021_9_23
    • ID: r42bccr9
    Snippet: SIMPLE SUMMARY: Little information has been reported about the impact of the COVID-19 pandemic in Philadelphia-negative chronic myeloproliferative neoplasms (MPN). In this review, we summarize the knowledge about MPN clinical management, including cytoreductive and antiplatelet/anticoagulant therapy, thrombotic risk, prognosis, and vaccination strategies at the time of COVID-19. ABSTRACT: An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in China
    Document: SIMPLE SUMMARY: Little information has been reported about the impact of the COVID-19 pandemic in Philadelphia-negative chronic myeloproliferative neoplasms (MPN). In this review, we summarize the knowledge about MPN clinical management, including cytoreductive and antiplatelet/anticoagulant therapy, thrombotic risk, prognosis, and vaccination strategies at the time of COVID-19. ABSTRACT: An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in China and then become pandemic in February 2020. Several publications investigated the possible increased rate of COVID-19 infection in hematological malignancies. Based on the published data, strategies for the management of chronic Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are provided. The risk of severe COVID-19 seems high in MPN, particularly in patients with essential thrombocythemia, but not negligible in myelofibrosis. MPN patients are at high risk of both thrombotic and hemorrhagic complications and this must be accounted in the case of COVID-19 deciding on a case-by-case basis. There are currently no data to suggest that hydroxyurea or interferon may influence the risk or severity of COVID-19 infection. Conversely, while the immunosuppressive activity of ruxolitinib might pose increased risk of infection, its abrupt discontinuation during COVID-19 syndrome is associated with worse outcome. All MPN patients should receive vaccine against COVID-19; reassuring data are available on efficacy of mRNA vaccines in MPNs.

    Search related documents:
    Co phrase search for related documents
    • abdominal symptom and acute phase: 1
    • abdominal symptom and acute sars cov respiratory syndrome coronavirus: 1, 2
    • abnormal production and acute infection: 1, 2, 3
    • abnormal production and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • absolute neutrophil and active therapy: 1
    • absolute neutrophil and acute infection: 1, 2, 3, 4, 5
    • absolute neutrophil and acute leukemia: 1, 2, 3, 4, 5
    • absolute neutrophil and acute phase: 1, 2, 3, 4, 5, 6, 7
    • absolute neutrophil and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • absolute neutrophil count and active therapy: 1
    • absolute neutrophil count and acute infection: 1, 2, 3, 4, 5
    • absolute neutrophil count and acute leukemia: 1, 2, 3, 4, 5
    • absolute neutrophil count and acute phase: 1, 2, 3, 4, 5, 6
    • absolute neutrophil count and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6
    • active surveillance and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • active surveillance and acute phase: 1, 2
    • active surveillance and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active therapy and acute phase: 1
    • active therapy and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16